These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 16138637)

  • 1. [Advantages of fast-acting insulin analogs: preprandial greater HbA1c lowering -- postprandial lower weight].
    MMW Fortschr Med; 2005 Aug; 147(33-34):45. PubMed ID: 16138637
    [No Abstract]   [Full Text] [Related]  

  • 2. Will the use of insulin analogs improve glycemic control during adolescence?
    Dunger DB
    Pediatr Diabetes; 2003 Jun; 4(2):61-3. PubMed ID: 14655260
    [No Abstract]   [Full Text] [Related]  

  • 3. Studies show Lantus to be effective, safe and flexible in the treatment of type 1 diabetes.
    Walczak IM
    Diabetes Technol Ther; 2002; 4(5):744-5. PubMed ID: 12458569
    [No Abstract]   [Full Text] [Related]  

  • 4. [New fast-acting insulin analog. This insulin profits type l and type 2 diabetics].
    Wepner U
    MMW Fortschr Med; 2004 Nov; 146(47):62-3. PubMed ID: 15624662
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of mixing glargine and short-acting insulin analogs on glucose control.
    Kaplan W; Rodriguez LM; Smith OE; Haymond MW; Heptulla RA
    Diabetes Care; 2004 Nov; 27(11):2739-40. PubMed ID: 15505016
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine.
    Ohta A; Arai K; Nishine A; Sada Y; Kato H; Fukuda H; Asai S; Nagai Y; Katabami T; Tanaka Y
    Endocr J; 2013; 60(2):173-7. PubMed ID: 23047542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [American Diabetes Association's Annual Meeting: new data on insulin glargine: early combination promises more success].
    MMW Fortschr Med; 2005 Aug; 147(33-34):44-5. PubMed ID: 16138636
    [No Abstract]   [Full Text] [Related]  

  • 8. Insulin glargine clinical trials.
    White JR
    Clin Ther; 2004 Jul; 26(7):1179-81; discussion 1182-3. PubMed ID: 15336483
    [No Abstract]   [Full Text] [Related]  

  • 9. [An update on multiple insulin injection therapy in type 1 and 2 diabetes].
    Varanauskiene E; Varanauskaite I; Ceponis J
    Medicina (Kaunas); 2006; 42(9):770-9. PubMed ID: 17028476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment.
    Lepore G; Dodesini AR; Nosari I; Trevisan R
    Diabetes Care; 2003 Apr; 26(4):1321-2. PubMed ID: 12663625
    [No Abstract]   [Full Text] [Related]  

  • 11. Fasting and insulin glargine in individuals with type 1 diabetes.
    Mucha GT; Merkel S; Thomas W; Bantle JP
    Diabetes Care; 2004 May; 27(5):1209-10. PubMed ID: 15111549
    [No Abstract]   [Full Text] [Related]  

  • 12. [For each diabetic the right program. Insulin therapy according to the physiology model].
    Bischoff A
    MMW Fortschr Med; 2003 Aug; 145(31-32):10. PubMed ID: 14524061
    [No Abstract]   [Full Text] [Related]  

  • 13. Initiation of insulin therapy in patients with type 2 diabetes failing oral therapy: response to Mikhail and Cope and to Janka.
    Raskin P
    Diabetes Care; 2005 Nov; 28(11):2811. PubMed ID: 16249569
    [No Abstract]   [Full Text] [Related]  

  • 14. Postprandial rather than preprandial glucose levels should be used for adjustment of rapid-acting insulins.
    Bell DS; Ovalle F; Shadmany S
    Endocr Pract; 2000; 6(6):477-8. PubMed ID: 11155223
    [No Abstract]   [Full Text] [Related]  

  • 15. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis.
    Sharplin P; Gordon J; Peters JR; Tetlow AP; Longman AJ; McEwan P
    Cardiovasc Diabetol; 2009 Feb; 8():9. PubMed ID: 19220880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy.
    Albright ES; Desmond R; Bell DS
    Diabetes Care; 2004 Feb; 27(2):632-3. PubMed ID: 14747268
    [No Abstract]   [Full Text] [Related]  

  • 17. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similar A1C outcomes in type 1 diabetic patients undergoing intensive diabetes management with preprandial rapid-acting insulin and either CSII or glargine.
    Harmel AP; Mathur R
    Diabetes Care; 2004 Jan; 27(1):272-3. PubMed ID: 14694001
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical experiences with Lantus therapy in Swedish routine health care].
    Löndahl M; Nilsson A; Katzman P
    Lakartidningen; 2005 Sep 5-11; 102(36):2503, 2505. PubMed ID: 16196437
    [No Abstract]   [Full Text] [Related]  

  • 20. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR; Gilbert RE; Yue DK
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.